Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Synlogic (DE:MIN)
BERLIN:MIN
Synlogic (MIN) Stock Price & Analysis
0 Followers
MIN Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.26 - €7.44
Previous Close€1.4
Volume0.00
Average Volume (3M)367.00
Market Cap
€16.25M
Enterprise Value-€375.97K
Total Cash (Recent Filing)$32.31M
Total Debt (Recent Filing)$14.46M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 08, 2024EPS Estimate
-€0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,707,011
10 Day Avg. Volume0
30 Day Avg. Volume367
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.31
Price to Sales (P/S)0.92
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.12
Enterprise Value/Gross Profit-0.11
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
€0.94Price Target Upside-33.19% Downside
Rating ConsensusHold
Number of Analyst Covering1
Synlogic News
PremiumCompany Announcements
Synlogic Appoints James Flynn to Board Amidst Director Resignations
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe anticipation of first look data from Synpheny-3 could significantly boost investor interest in labafenogene marselecobac, with potential implications for understanding its effects.
Market ExpansionLabafenogene marselecobac may have the potential to treat younger PKU patients, potentially expanding its market reach and benefiting a wider patient demographic.
Target MarketSYBX has the potential to capture a substantial portion of the PKU patient market in the US, aiming to treat those who are not responsive to current treatments.
Bears Say
Analyst SentimentA downgrade to Market Perform following the discontinuation of Synlogic's lead program suggests a bleak outlook for the stock, as analyst expectations adjust to the new developments.
Clinical Trial FailureSynlogic's discontinuation of their lead program SYNB1934 in phenylketonuria due to lack of efficacy puts a serious dent in investor confidence, potentially impacting the stock's performance.
Operational DownscalingSynlogic's decision to wind down operations and execute a workforce reduction by more than 90% signals significant troubles ahead for the company's sustainability and stock value.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
53.74% Other Institutional Investors
46.26% Public Companies and
Individual Investors
MIN FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest stock price was €0.26 and its highest was €7.44 in the past 12 months.
What is Synlogic’s market cap?
Currently, no data Available
When is Synlogic’s upcoming earnings report date?
Synlogic’s upcoming earnings report date is Aug 08, 2024 which is in 36 days.
How were Synlogic’s earnings last quarter?
Synlogic released its earnings results on May 14, 2024. The company reported -€2.422 earnings per share for the quarter, missing the consensus estimate of -€0.764 by -€1.658.
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate is -€0.48.
How many shares outstanding does Synlogic have?
Currently, no data Available
What happened to Synlogic’s price movement after its last earnings report?
Synlogic reported an EPS of -€2.422 in its last earnings report, missing expectations of -€0.764. Following the earnings report the stock price went down -2.395%.
Which hedge fund is a major shareholder of Synlogic?
Among the largest hedge funds holding Synlogic’s share is RA Capital Management. It holds Synlogic’s shares valued at N/A.
---
Synlogic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€0.94 (-33.19% Downside)
€0.94 (-33.19% Downside)
Blogger Sentiment
Bearish
DE:MIN Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $968.8 over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.89%
12-Months-Change
Fundamentals
Return on Equity
-178.51%
Trailing 12-Months
Asset Growth
-61.41%
Trailing 12-Months
Company Description
Synlogic
Synlogic, Inc. is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.
---
MIN Stock 12 Month Forecast
Average Price Target
€0.94
▼(-33.19% Downside)
Technical Analysis
Synlogic
―
Aileron Therapeutics
―
Bioline RX Ltd Sponsored ADR
―
Mersana Therapeutics
―
Corbus Pharmaceuticals
―
Best Analysts Covering MIN
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-51.10%
initiated a buy rating 7 months ago
Copying James Molloy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -51.10% per trade.
---